Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
LUCD
$1.46
$
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Next Earnings
2026-02-25
Beta
1.224
Average Volume
Market Cap
Last Dividend
CIK
0001799011
ISIN
US54948X1090
CUSIP
54948X109
CEO
Lishan Aklog
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
72
IPO Date
2021-10-14
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Lucid Diagnostics (NASDAQ:LUCD) & Alpha Tau Medical (NASDAQ:DRTS) Financial Survey | Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation. Insider and Institutional Ownership 2.7% of | Defense World | 2026-02-20 04:44:58 |
| Inogen (INGN) Soars 6.6%: Is Further Upside Left in the Stock? | Inogen (INGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | Zacks Investment Research | 2026-02-12 08:11:14 |
| PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities | Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance sheet NEW YORK, Feb. 4, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced the closing of preferred stock and senior secured note financings by existing long-term investors, resulting in the elimination of a significant legacy capital structure overhang from previously outstanding convertible securities and a materially strengthened balance sheet. The Company has issued $30 million of newly designated Series D Convertible Preferred Stock with warrants exercisable for up to an additional $30 million of Series D Convertible Preferred Stock, callable upon publication of a positive draft Medicare local coverage determination (LCD) for the EsoGuard Esophageal DNA Test offered by its subsidiary, Lucid Diagnostics, Inc. (Nasdaq: LUCD) ("Lucid"). | PRNewsWire | 2026-02-04 08:01:00 |
| Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard® | NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test , expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually. The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate determined by the Centers for Medicare & Medicaid Services (CMS), enabling VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework. | PRNewsWire | 2026-01-21 08:00:00 |
| Contrasting Lucid Diagnostics (NASDAQ:LUCD) & Waters (NYSE:WAT) | Waters (NYSE: WAT - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Earnings and Valuation This table compares Waters and Lucid | Defense World | 2026-01-10 02:04:58 |
| Reviewing Intuitive Surgical (NASDAQ:ISRG) and Lucid Diagnostics (NASDAQ:LUCD) | Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) and Intuitive Surgical (NASDAQ: ISRG - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Earnings and Valuation This table compares Lucid Diagnostics | Defense World | 2026-01-02 01:54:52 |
| Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection | Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device Real-world data confirm excellent technical performance, very rapid cell-collection times, and appropriate physician use, consistent with previously published studies NEW YORK , Dec. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced new data from the largest reported real-world experience of non-endoscopic esophageal precancer (Barrett's esophagus or BE) detection, which evaluated its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device . The manuscript, entitled Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients , is currently available on the leading health sciences preprint server, medRxiv, while undergoing peer review for publication. | PRNewsWire | 2025-12-09 08:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| SC 13D/A | 2026-02-09 | 2026-02-09 | View Filing |
| S-3 | 2025-12-05 | 2025-12-05 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13D/A | 2025-10-10 | 2025-10-10 | View Filing |
| 4 | 2025-10-07 | 2025-10-07 | View Filing |
| 3 | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| 424B5 | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 424B5 | 2025-09-09 | 2025-09-09 | View Filing |
| 4 | 2025-08-22 | 2025-08-22 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| 424B3 | 2025-06-03 | 2025-06-03 | View Filing |
| EFFECT | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| 424B5 | 2025-05-30 | 2025-05-30 | View Filing |
| 4/A | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| S-3 | 2025-05-22 | 2025-05-21 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| DEFA14A | 2025-04-30 | 2025-04-30 | View Filing |
| ARS | 2025-04-30 | 2025-04-30 | View Filing |
| DEF 14A | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-25 | 2025-04-25 | View Filing |
| PRE 14A | 2025-04-18 | 2025-04-18 | View Filing |
| 8-K | 2025-04-11 | 2025-04-11 | View Filing |
| 424B5 | 2025-04-10 | 2025-04-10 | View Filing |
| 8-K | 2025-04-10 | 2025-04-10 | View Filing |
| 424B5 | 2025-04-09 | 2025-04-09 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-05 | 2025-03-05 | View Filing |
| 424B5 | 2025-03-05 | 2025-03-05 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-02-25 | 2025-02-24 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| S-8 | 2025-01-31 | 2025-01-31 | View Filing |
| S-8 | 2025-01-31 | 2025-01-31 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| SC 13D/A | 2024-12-12 | 2024-12-12 | View Filing |
| D | 2024-12-06 | 2024-12-06 | View Filing |
| 8-K | 2024-11-29 | 2024-11-29 | View Filing |
| 8-K | 2024-11-18 | 2024-11-18 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-07-24 | 2024-07-23 | View Filing |
| 424B3 | 2024-07-19 | 2024-07-19 | View Filing |
| EFFECT | 2024-07-19 | 2024-07-19 | View Filing |
| S-3/A | 2024-07-12 | 2024-07-12 | View Filing |
| SC 13G/A | 2024-07-08 | 2024-07-08 | View Filing |
| S-3 | 2024-07-01 | 2024-07-01 | View Filing |
| 8-K | 2024-06-21 | 2024-06-21 | View Filing |
| DEF 14A | 2024-06-06 | 2024-06-06 | View Filing |
| DEFA14A | 2024-06-06 | 2024-06-06 | View Filing |
| PRE 14A | 2024-05-24 | 2024-05-24 | View Filing |
| DEFA14A | 2024-05-24 | 2024-05-24 | View Filing |
| 8-K | 2024-05-24 | 2024-05-24 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| 4 | 2024-05-09 | 2024-05-09 | View Filing |
| 3 | 2024-05-09 | 2024-05-09 | View Filing |
| 4 | 2024-05-08 | 2024-05-08 | View Filing |
| 4 | 2024-05-08 | 2024-05-08 | View Filing |
| 4 | 2024-05-08 | 2024-05-08 | View Filing |
| 4 | 2024-05-08 | 2024-05-08 | View Filing |
| 8-K | 2024-05-07 | 2024-05-07 | View Filing |
| 8-K | 2024-05-02 | 2024-05-02 | View Filing |
| DEFA14A | 2024-04-29 | 2024-04-29 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 3,638.21% | 0.82 | 39 | 0.76 | 288.46 | 3500.96 |
| Larry Williams PercentR Strategy | 3,638.21% | 0.82 | 39 | 0.76 | 288.46 | 3500.96 |
| Neural Forcast | 795.02% | 1 | 20 | 0.84 | 1988.96 | 657.76 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | x | xxxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxx% | xxxx | x | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | xxxx | xxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxx | xxxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxxx | xxxxxx |